We are live on ! Find out more
EPZM

Epizyme, Inc
EPZM

Delisted

EPZM was delisted on the 11th of August, 2022.

Back to rankings

0 hedge funds and large institutions have $4K invested in Epizyme, Inc in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 93 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 93 → 0 (-93)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $187M → $4K (-$187M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 93

Holders
–
Holders Change
-93
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
93
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
RM
RP Management
New York
-$46.8M
2
Primecap Management
Primecap Management
California
-$24.5M
3
NM
Newtyn Management
New York
-$11.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$11.1M
5
RSCM
Rock Springs Capital Management
Maryland
-$11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Tudor Investment Corp
1
Tudor Investment Corp
Connecticut
$4K -$324K -218,384 Closed
RM
2
RP Management
New York
– -$46.8M -31,841,394 Closed
Primecap Management
3
Primecap Management
California
– -$24.5M -16,642,727 Closed
NM
4
Newtyn Management
New York
– -$11.1M -7,569,995 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$11.1M -7,540,469 Closed
RSCM
6
Rock Springs Capital Management
Maryland
– -$11M -7,485,543 Closed
PAI
7
Palo Alto Investors
California
– -$9.96M -6,774,541 Closed
PIM
8
Platinum Investment Management
Australia
– -$9.71M -6,603,870 Closed
RCMNY
9
Rubric Capital Management (New York)
New York
– -$9.24M -6,283,690 Closed
WP
10
Woodline Partners
California
– -$5.68M -3,866,148 Closed
BlackRock
11
BlackRock
New York
– -$5.4M -3,673,443 Closed
MB
12
MPM BioImpact
Massachusetts
– -$5.04M -3,425,202 Closed
LCM
13
Laurion Capital Management
New York
– -$4.24M -2,885,100 Closed
Goldman Sachs
14
Goldman Sachs
New York
– -$3.87M -2,629,998 Closed
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
– -$2.54M -1,728,102 Closed
Millennium Management
16
Millennium Management
New York
– -$2.28M -1,548,767 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$2.23M -1,518,496 Closed
BCM
18
Beryl Capital Management
California
– -$2.05M -1,394,821 Closed
BBA
19
Baker Bros. Advisors
New York
– -$1.47M -1,000,000 Closed
GCP
20
GSA Capital Partners
United Kingdom
– -$1.37M -930,718 Closed
GF
21
Gabelli Funds
New York
– -$1.25M -852,105 Closed
Morgan Stanley
22
Morgan Stanley
New York
– -$1.23M -836,955 Closed
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
– -$1.18M -805,798 Closed
FLSM
24
Frazier Life Sciences Management
California
– -$1.09M -739,369 Closed
State Street
25
State Street
Massachusetts
– -$1.03M -700,331 Closed
1
2 3 4

EPZM Hedge Fund Activity: Q3 2022 in Review

0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2022, worth a combined $4K — down 100% from $187M a quarter earlier.

Sellers outnumbered buyers: 93 funds closed out of EPZM and 0 opened new positions — a net loss of 93 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was RP Management, exiting entirely with an estimated $46.8M sold.

  • 0 institutional investors held Epizyme, Inc (EPZM) as of Q3 2022, down from 93 in Q2 2022.
  • Funds reported $4K of Epizyme, Inc stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Epizyme, Inc positions in Q3 2022 and 93 closed out, a net change of -93 holders.
  • The largest Epizyme, Inc seller in Q3 2022 was RP Management, an estimated $46.8M sold.

Based on aggregated 13F filings for Q3 2022.